Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic assessment of disease activity in IBD. By merging data science with clinical expertise, ARGES provides a continuous disease severity score in UC, moving beyond the traditional categorical, human-read Mayo Endoscopic Subscore (MES), which sorts severity into fixed categories.
